Does serial administration of gadolinium-based contrast agents affect patient neurological and neuropsychological status? Fourteen-year follow-up of patients receiving more than fifty contrast administrations
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu dopisy, práce podpořená grantem
PubMed
31664740
PubMed Central
PMC7318267
DOI
10.1002/jmri.26948
Knihovny.cz E-zdroje
- MeSH
- gadolinium MeSH
- kontrastní látky * MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- mozečková jádra MeSH
- následné studie MeSH
- organokovové sloučeniny * MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- dopisy MeSH
- práce podpořená grantem MeSH
- Názvy látek
- gadolinium MeSH
- kontrastní látky * MeSH
- organokovové sloučeniny * MeSH
Department of Neurology Clinical Psychology Na Homolce Hospital Prague Czech Republic
Department of Radiology Na Homolce Hospital Prague Czech Republic
Zobrazit více v PubMed
European Society of Urogenital Radiology (ESUR) guidelines on contrast agents, Version 10.0. [http://www.esur-cm.org/].
Kanda T, Fukusato T, Matsuda M, et al. Gadolinium‐based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: Evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015;276:228–232. PubMed
European Medicines Agency: EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans. [https://www.ema.europa.eu/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents_en.pdf].
Gillies MJ, Hyam JA, Weiss AR, et al. The cognitive role of the globus pallidus interna: Insights from disease states. Exp Brain Res 2017;235:1455–1465. PubMed PMC
Payan CA, Viallet F, Landwehrmeyer BG, et al. Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: Validation of the NNIPPS—Parkinson Plus Scale. PLoS One 2011;6:e22293. PubMed PMC
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: A clinical review. JAMA 2013;310:1842–1850. PubMed
Rulseh AM, Keller J, Klener J, et al. Long‐term survival of patients suffering from glioblastoma multiforme treated with tumor‐treating fields. World J Surg Oncol 2012;10:220. PubMed PMC
Welk B, McArthur E, Morrow SA, et al. Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA 2016;316:96–98. PubMed
Forslin Y, Shams S, Hashim F, et al. Retention of gadolinium‐based contrast agents in multiple sclerosis: Retrospective analysis of an 18‐year longitudinal study. AJNR Am J Neuroradiol 2017;38:1311–1316. PubMed PMC
Cocozza S, Pontillo G, Lanzillo R, et al. MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in multiple sclerosis. Neuroradiology 2019;61:155–162. PubMed
